Gerresheimer's weight-loss drug deals pipeline helps profits meet forecasts
Adds guidance in paragraph 4, CEO comment in paragraph 3-5, analyst comment in paragraph 6
By Isabel Demetz
July 11 (Reuters) -Medical equipment group Gerresheimer GXIG.DE posted second-quarter adjusted core profit in line with expectations on Thursday, driven by the deal pipeline for its plastics and devices business, which supplies weight-loss drug makers with autoinjector pens.
The company confirmed guidance for the mid-term that its deals with weight-loss drug manufacturers, such as Novo Nordisk NOVOb.CO, are expected to bring at least 350 million euros ($379.44 million) of annual revenue over the next three years, despite lower demand in its primary packaging glass division.
Gerresheimer's results were hit by negative destocking effects, which are expected to remain an issue for the third quarter, CEO Dietmar Siemssen said during a conference call.
"We therefore estimate revenue growth to be around the lower end of our guidance range for 2024," he added.
Siemssen also said the company is set for further growth due to ramp ups in its projects and production lines. The GLP-1 (weight-loss) market is on the rise and it's a similar picture in Gerresheimer, he added.
"We’d expect shares to respond positively on the update given the earnings beat and no change to guidance," Berenberg analysts said.
Gerresheimer shares were up around 2.7% at 1003 GMT.
Adjusted core profit came in at 107.3 million euros in the quarter, slightly above analysts' average forecast of 104.7 million euros compiled by Vara Research, the company said.
The medical technology company also confirmed its earnings guidance for 2024.
($1 = 0.9224 euros)
Reporting by Isabel Demetz; Editing by Kim Coghill, Rashmi Aich and Jane Merriman
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
